Intensity Therapeutics Inc (NASDAQ: INTS) kicked off on Tuesday, down -3.21% from the previous trading day, before settling in for the closing price of $0.31. Over the past 52 weeks, INTS has traded in a range of $0.19-$4.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -23.29% over the past five years. While this was happening, its average annual earnings per share was recorded 62.22%. With a float of $40.09 million, this company’s outstanding shares have now reached $47.06 million.
Intensity Therapeutics Inc (INTS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intensity Therapeutics Inc is 14.80%, while institutional ownership is 6.83%.
Intensity Therapeutics Inc (INTS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.25 earnings per share (EPS), higher than consensus estimate (set at -0.31) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.33% during the next five years compared to -23.29% drop over the previous five years of trading.
Intensity Therapeutics Inc (NASDAQ: INTS) Trading Performance Indicators
Take a look at Intensity Therapeutics Inc’s (INTS) current performance indicators. Last quarter, stock had a quick ratio of 1.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Intensity Therapeutics Inc (INTS)
Intensity Therapeutics Inc (NASDAQ: INTS) saw its 5-day average volume 5.06 million, a positive change from its year-to-date volume of 1.76 million. As of the previous 9 days, the stock’s Stochastic %D was 69.17%.
During the past 100 days, Intensity Therapeutics Inc’s (INTS) raw stochastic average was set at 6.43%, which indicates a significant decrease from 72.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0284 in the past 14 days, which was lower than the 0.0725 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3021, while its 200-day Moving Average is $1.4709. Nevertheless, the first resistance level for the watch stands at $0.3166 in the near term. At $0.3313, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3396. If the price goes on to break the first support level at $0.2936, it is likely to go to the next support level at $0.2853. The third support level lies at $0.2706 if the price breaches the second support level.
Intensity Therapeutics Inc (NASDAQ: INTS) Key Stats
The company with the Market Capitalisation of 14.21 million has total of 47,058K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -16,270 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -2,540 K.
